Too many middlemen disconnects you from patients.

See How Close
Lost in Transition Telephones
Lost in Transition

Treating rare disease shouldn’t be like a bad game of telephone, with each step generating chaos and confusion. Patient adherence suffers, quality of care diminishes, manufacturers miss out on vital feedback and cost goes up. But imagine if you could cut past all that. We did.

Learn More

News Details

June 21, 2017

Dohmen proudly sponsors the 26th Alpha-1 National Education Conference, June 23-25

The Dohmen Life Science Services (DLSS) team will join hundreds of rare disease experts, patients and caregivers at the 26th Alpha-1 National Education Conference in Chicago, IL.

 

Hosted by the Alpha-1 Foundation, this year’s conference focuses on “Mission. Inspiration. Determination. Innovation.” Patients and caregivers will hear global experts discuss progress and research in the treatment of the rare lung and liver disease.

 

Alpha-1 antitrypsin deficiency affects at least 100,000 people in the United States, but fewer than 10 percent have been properly diagnosed. It can lead to lung and liver diseases and is the most common known genetic cause of emphysema and is often called "genetic COPD."


“The health implications of Alpha-1 are unique and vary from patient to patient, requiring specialized support,” said Kathi Henson, Senior Vice President, Patient and Client Services, DLSS. “We understand the unique needs of these patients and have created a custom service wrap around to support them, leading to better patient health, higher adherence and greater patient loyalty.”

 

This year’s conference will also pay special tribute to the Foundation’s founder, John W. Walsh, who passed away in March after providing 20 years of exceptional leadership.


Portions of Saturday’s conference agenda, including the John W. Walsh memorial dinner, will be streaming live on the Foundation’s Facebook page. For more information, visit www.alpha1.org and to see the event’s agenda visit here.